# Aro Biotherapeutics Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aro-biotherapeutics-company

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.arobiotx.com
- Total disclosed funding: $66M
- Latest round: Series B (Dec 13, 2022)
- Investors on record: 8

## About

Aro Biotherapeutics Company, based in the US, focuses on developing innovative tissue-targeted genetic medicines using their proprietary Centyrin technology to address challenging diseases.Founded in 2018 in Philadelphia, US, Aro Biotherapeutics Company develops tissue-targeted genetic medicines. The firm has completed 4 deals, with the most recent funding round being a Series B on December 13, 2022, raising USD 24.033 mn led by Cowen Healthcare Investments along with investors including Johnson & Johnson Innovation, HealthCap, and BVF Partners. The company was co-founded by Karyn Neil and Susan Dillon, who also serves as the CEO.Aro Biotherapeutics specializes in the development of tissue-targeted genetic medicines through its proprietary Centyrin technology. The company’s primary offerings include a pipeline of Centyrin-RNA drug conjugates aimed at precisely modulating gene targets associated with various diseases, particularly those previously deemed difficult to treat. These products utilize receptor-specific Centyrins conjugated with oligonucleotides, ensuring targeted delivery of therapeutic agents to disease tissues. Aro's focus extends to addressing conditions such as Late-Onset Pompe Disease (LOPD), with ongoing clinical trials evaluating the efficacy of their therapeutic candidates. The company primarily serves patients and healthcare providers in the United States, with aspirations to expand into broader international markets.Aro Biotherapeutics generates revenue through a combination of partnerships, clinical trial funding, and potential future product sales. The company's business transactions are structured around collaborations with industry partners, which may include revenue-sharing agreements or milestone payments linked to the progress of their clinical programs. Additionally, the firm engages in B2B transactions, focusing on securing contracts with healthcare organizations and research institutions for the development and commercialization of its Centyrin-based therapeutics. As their drug candidates advance through clinical trials, Aro anticipates revenue streams from successful partnerships and collaborations that could facilitate the eventual launch of their innovative treatments into the market.In November 2023, Aro Biotherapeutics Company raised USD 41.5 mn in Series B funding, led by returning investor Cowen Healthcare Investments with participation from Johnson & Johnson Innovation, Northpond Ventures, HealthCap, and BVF Partners. The company plans to utilize this funding to support product development initiatives. Aro is focused on launching new products and expanding into international markets. Specific target regions for expansion will be announced as the company progresses with its clinical trials and product development.

## Funding rounds

- Series B, Dec 13, 2022, $24M — HealthCap, Johnson & Johnson Innovation, BVF Partners, Northpond Ventures, Cowen Healthcare Investments
- Series A, Dec 21, 2020, $42M — HealthCap, Johnson & Johnson Innovation, BioMotiv, BVF Partners, Ridgeback Capital Management, Northpond Ventures, Cowen Healthcare Investments, Ionis Pharmaceuticals, Inc.

## Investors

- HealthCap — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- BioMotiv — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- Ridgeback Capital Management — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- Cowen Healthcare Investments — Series A, Series B
- Ionis Pharmaceuticals, Inc. — Series A